KMT2A and acute myeloid leukemia: Since the MLL-AF9GFP cells did not show susceptibility in vivo to the Minnelide dose being used, this AML was selected to enable evaluation of GVT activity following aHSCT and results showed that the antitumor response was maintained concurrent with a reduction in GVHD.